Giuliana Grossi

The FDA has approved oveporexton (Orzeyful), the first orexin agonist for narcolepsy type 1, based on phase 3 data showing broad symptom improvement.

Policy makers should vet the methodology behind reported cost savings before trusting the numbers, says Halima Ahmadi-Montecalvo, PhD, MPH.

Clinicians outline fragmented obesity and diabetes care models, insurance-driven prescribing, and early results from Medicare's GLP-1 bridge program.

The FDA approved daraxonrasib (Rasonque), the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy.

Nearly 1 in 3 women aged 21 to 29 and 1 in 7 aged 30 to 65 had never been screened for cervical cancer by 2023.

Atlanta clinicians described obesity care that stalls between routine diagnosis and delayed treatment, with coverage rules driving therapy choices.

At a Chicago roundtable, clinicians detailed fragmented obesity and diabetes care, transplant-access barriers, and insurance-driven prescribing decisions.

A study found no direct trial evidence for natalizumab or its biosimilar in MS and found limited cost-effectiveness vs most alternatives.

DOJ policy shifts have put HHS on the same side as states seeking to narrow Section 504's disability integration mandate in Texas v Kennedy.

Transplant weight-loss access, a new dermatomyositis drug, mifepristone safety views, and racial gaps in cataract surgery and CRC mortality.